Silverarc Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Silverarc Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-218,975	Closed	-$5.17M	–	99
2023 Q4	$5.17M	Sell	218,975 -371,025	-63%	-$6.61M	1.54%	28
2023 Q3	$8.8M	Buy	590,000 +430,000	+269%	+$5.7M	2.67%	8
2023 Q2	$1.75M	Buy	+160,000	New	+$1.49M	0.54%	48

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's CBAY Position: Q1 2024 in Review

Silverarc Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 218,975 shares — an estimated $5.17M sold.

Silverarc Capital Management first reported a position in CBAY in Q2 2023 and held it in 3 quarters. The position peaked at $8.8M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Silverarc Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Silverarc Capital Management sold 218,975 Cymabay Therapeutics shares in Q1 2024, an estimated $5.17M.
Silverarc Capital Management first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 3 quarters.
Silverarc Capital Management's Cymabay Therapeutics position peaked at $8.8M in Q3 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.